The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Smart pH-Sensitive and Temporal-Controlled Polymeric Micelles for Effective Combination Therapy of Doxorubicin and Disulfiram
Abstract
The combination of a chemotherapeutic drug with a multidrug resistance (MDR) modulator has emerged as a promising strategy for treating MDR cancer. To ensure two drugs could be simultaneously delivered to tumor region at the optimum ratio, and the MDR modulator could be released earlier and faster than the chemotherapeutic drug to inactivate P-glycoprotein (P-gp) and subsequently inhibit the pumping out of the chemotherapeutic drug, a smart pH-sensitive polymeric micelles system with high drug loading and precise drug ratio was designed and prepared by conjugating doxorubicin (DOX) to poly(styrene-co-maleic anhydride) (SMA) derivative with adipic dihydrazide (ADH) through a acid-cleavable hydrazone bond, and then encapsulating disulfiram (DSF), a P-gp inhibitor as well as an apoptosis inducer, into the micelles formed by the self-assembly of SMA-ADH-DOX (SAD) conjugate. The pH-sensitive polymeric micelles system enabled a temporal release of two drugs: encapsulated DSF was released fast to inhibit the activity of P-gp and restore cell apoptotic signaling pathways, while conjugated DOX was released in a sustained and pH-dependent manner and highly accumulated in drug resistant cells to exert therapeutic effect, due to the inactivation of P-gp by DSF. The smart co-delivery system was very effective in enhancing the cytotoxicity by increasing the intracellular accumulation of DOX and promoting the apoptotic response, and showed the most effective inhibitory effect on the growth of drug-resistant breast cancer xenografts as compared to other combinations of both drugs. In a word, this smart co-delivery system has significant promise for the clinical therapy of MDR cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Xiao, K., Li, Y., Luo, J., Lee, J. S., Xiao, W., Gonik, A. M., Agarwal, R. G., & Lam, K. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.021 · Cited by 1,039
Self-citationSynergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Duan, X., & Li, Y. (2013) · Small · doi:10.1002/smll.201201390 · Cited by 926
Self-citationWang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2126 · Cited by 674
Greco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
Nam, H. Y., Kwon, S. M., Chung, H., Lee, S.-Y., Kwon, S.-H., Jeon, H., Kim, Y., Park, J. H., Kim, J., Her, S., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.018 · Cited by 564
Phase III and submission failures: 2007–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Yip, N. C., Fombon, I. S., Liu, P., Brown, S., Kannappan, V, Armesilla, A. L., Xu, B., Cassidy, J., Darling, J. L., & Wang, W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.126 · Cited by 421
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
Silica Nanorattle–Doxorubicin-Anchored Mesenchymal Stem Cells for Tumor-Tropic Therapy
Li, L., Guan, Y., Liu, H., Hao, N., Liu, T., Meng, X., Fu, C., Li, Y., Qu, Q., Zhang, Y., et al. (2011) · ACS Nano · doi:10.1021/nn202399w · Cited by 327
Self-citationDevelopment of Novel Combination Therapies
Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248
Nanomaterial standards for efficacy and toxicity assessment
Adiseshaiah, P. P., Hall, J. B., & McNeil, S. E. (2010) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.66 · Cited by 238
Reinhardt, H. C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M. A. T. M., Wang, X., Linding, R., Ong, S.-E., Weaver, D., Carr, S. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.018 · Cited by 238
Wang, W., McLeod, H. L., & Cassidy, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.10972 · Cited by 226
Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 212
Mechanism of Cellular Uptake of Highly Fluorescent Conjugated Polymer Nanoparticles
Fernando, L. P., Kandel, P. K., Yu, J., McNeill, J., Ackroyd, P. C., & Christensen, K. A. (2010) · Biomacromolecules · doi:10.1021/bm1007103 · Cited by 196
Guo, X., Xu, B., Pandey, S., Goessl, E., Brown, J. E. P., Armesilla, A. L., Darling, J. L., & Wang, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.002 · Cited by 138
Lövborg, H., Oberg, F. G., Rickardson, L., Gullbo, J., Nygren, P., & Larsson, R. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21534 · Cited by 127
Blockage of Drug Resistance In Vitro by Disulfiram, a Drug Used to Treat Alcoholism
Loo, T. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.898 · Cited by 108
Morrison, B. W., Doudican, N. A., Patel, K. R., & Orlow, S. J. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e328334131d · Cited by 106
Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism
Regev, R., Yeheskely‐Hayon, D., Katzir, H., & Eytan, G. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.032 · Cited by 95
Long-Circulating 15 nm Micelles Based on Amphiphilic 3-Helix Peptide–PEG Conjugates
Dong, H., Dube, N., Shu, J. Y., Seo, J. W., Mahakian, L. M., Ferrara, K. W., & Xu, T. (2012) · ACS Nano · doi:10.1021/nn301142r · Cited by 94
Flip-Flop of Doxorubicin across Erythrocyte and Lipid Membranes
Regev, R., & Eytan, G. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00326-2 · Cited by 82
Disulfiram Metabolites Permanently Inactivate the Human Multidrug Resistance P-Glycoprotein
Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049917l · Cited by 80
Coencapsulation of Arsenic‐ and Platinum‐based Drugs for Targeted Cancer Treatment
Chen, H., Pazicni, S., Krett, N. L., Ahn, R. W., Penner‐Hahn, J. E., Rosen, S. T., & O’Halloran, T. V. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903655 · Cited by 77
Kastantin, M. J., Missirlis, D., Black, M., Ananthanarayanan, B., Peters, D., & Tirrell, M. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp1001786 · Cited by 72
Pluronic L61 Accelerates Flip–Flop and Transbilayer Doxorubicin Permeation
Krylova, O. O., Melik‐Nubarov, N. S., Badun, G. A., Ksenofontov, A. L., Menger, F. M., & Yaroslavov, A. A. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200204621 · Cited by 68
Pentassuglia, L., Graf, M., Lane, H. A., Kuramochi, Y., Cote, G. M., Timolati, F., Sawyer, D. B., Zuppinger, C., & Suter, T. M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.02.001 · Cited by 67
Xu, B., Shi, P., Fombon, I. S., Zhang, Y., Huang, F., Wang, W., & Zhou, S.-Y. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.08.004 · Cited by 53
Pozza, E. D., Donadelli, M., Costanzo, C., Zaniboni, T., Dando, I., Franchini, M., Arpicco, S., Scarpa, A., & Palmieri, M. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.001 · Cited by 33
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
The Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Metadata
- Authors
- Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-06-10
- Volume
- 7
- Issue
- 7
- Pages
- 5858-5869
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W1965636780
- Cited by
- 379
- References
- 38
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
